VIEN DUC NGUYEN

Mr. VIEN DUC NGUYEN

Department of Anatomy and Regenerative Biology, Osaka Metropolitan University, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
HVHung Thai Vu
Hung Thai Vu
VNVIEN DUC NGUYEN
VIEN DUC NGUYEN
HIHiroko Ikenaga
Hiroko Ikenaga
TMTsutomu Matsubara
Tsutomu Matsubara
Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is a major disease worldwide whose effective treatment is challenging. Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily and function as ligand-activated transcription factors. To date, three distinct subtypes of PPARs have been characterized: PPARα, PPARβ/δ, and PPARγ. PPARα and PPARγ are crucial regulators of lipid metabolism that modulate the transcription of genes involved in fatty acid (FA), bile acid, and cholesterol metabolism. Many PPAR agonists, including natural (FAs, eicosanoids, and phospholipids) and synthetic (fibrate, thiazolidinedione, glitazar, and elafibranor) agonists, have been developed. Furthermore, recent advancements in nanoparticles (NPs) have led to the development of new strategies for MASLD/MASH therapy. This review discusses the applications of specific cell-targeted NPs and highlights the potential of PPARα- and PPARγ-targeted NP drug delivery systems for MASLD/MASH treatment.

9 October 2021 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
TNThi Phuong Thao Nguyen
Thi Phuong Thao Nguyen
VNVIEN DUC NGUYEN
VIEN DUC NGUYEN
CHChi-Nhan Ha-Thuc
Chi-Nhan Ha-Thuc
Quoc-Bao BuiQuoc-Bao Bui
Quoc-Bao Bui
PPPatrick Perré
Patrick Perré
Dang Mao NguyenDang Mao Nguyen
Dang Mao Nguyen

14 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
HVHung Thai Vu
Hung Thai Vu
VNVIEN DUC NGUYEN
VIEN DUC NGUYEN
TMTsutomu Matsubara
Tsutomu Matsubara
In recent years, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) has become a leading worldwide disease, and its therapies are facing many complexities. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear receptor (NR) superfamily and have three subtypes: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). They have been identified to be essential in the regulation of lipid metabolism by controlling the transcription of genes related to fatty acids, bile acids, and cholesterol metabolism. Many PPAR agonists have been reported, such as natural agonists (fatty acids, eicosanoids, and phospholipids) and synthetic ligands (fibrates, thiazolidinediones, glitazars, and elafibranor). PPAR-based chemicals have a breakthrough in the innovation of therapy for fatty liver disease. This review will provide an overview of how PPARα and PPARγ play roles in lipid homeostasis, discussing the consideration of their agonists as potential therapeutic agents for NAFLD/NASH.

23 October 2026 in Cell Biology and Toxicology
Verified
Journal Article
Open access
PDF file
VNVIEN DUC NGUYEN
VIEN DUC NGUYEN
ADAtsuko Daikoku
Atsuko Daikoku
MAMiku Ando
Miku Ando
MKMana Kosugi
Mana Kosugi
CKChiho Kadono
Chiho Kadono
TMTsutomu Matsubara
Tsutomu Matsubara
Acetaminophen (APAP) overdose is a major cause of acute liver injury that is primarily driven by oxidative stress and mitochondrial dysfunction resulting from excessive N-acetyl-p-benzoquinone imine formation. Although the transcription factor C/EBP homologous protein (CHOP) is markedly increased during APAP-induced liver injury (AILI), its functional role in hepatocellular stress responses remains unclear. In this study, we examined the role of CHOP in hepatic redox regulation during AILI and its relationship with Fos. Using wild-type and Chop-null mice, we found that CHOP deficiency significantly exacerbated AILI with elevated serum alanine aminotransferase levels and extensive necrosis. At the molecular level, CHOP deficiency led to impaired GSH-dependent antioxidant pathway induction and decreased hepatic reduced glutathione (GSH). Notably, APAP-induced Fos expression was strongly CHOP-dependent, and CHOP and FOS showed partial spatial overlap at the boundary between injured and preserved liver parenchyma. Promoter-reporter analysis and ChIP-qPCR further supported CHOP-dependent transcriptional regulation of Fos. These findings support a CHOP–FOS-associated antioxidant response that contributes to hepatic redox homeostasis by promoting GSH-dependent antioxidant defenses, thereby supporting hepatocyte adaptation during AILI. Graphical Abstract